Martin Shkreli, known as “Pharma Bro,” has been released from federal prison early. Shkreli, known for his smug demeanor, was convicted of securities fraud after becoming a target of near-universal scorn for price-gouging the life-saving HIV drug, daraprim, by over %4,000. Shkreli’s early release […]
Latest Stories
Bridging the Innovation Gap with Biopharma Partnerships
With impending patent expirations and increased drug development times, the biopharma industry faces an innovation gap. Bridging this gap and maintaining or increasing the pipeline replenishment rate is essential for revenue growth. However, this rate is also falling, with the 25 top biopharma […]
Japan Drug Lobby Asserts Pricing Scheme Driving Drug Crisis
For the first time in the week starting May 16th, Japan’s three major pharmaceutical trade associations joined forces to call for changes to the government’s drug pricing structure in order to prevent missing out on new drug innovation and expansion. While American and European drug companies have […]
Learning from Big Pharma to Optimize Psychedelic Drug Development
During a post-earnings conference call yesterday, May 17th, executives Atai Live Sciences N.V. explained what they’ve learned from Johnson & Johnson’s Spravato launch. The launch of Spravato, an esketamine treatment, was marred by its high price, inpatient delivery, and addiction potential, […]
How Investing in Public Health Will Strengthen America’s Health
Introduction and summary Most of the gains in life expectancy achieved in the 20th century came not from medical progress. Rather, they resulted from public health advances such as cleaner air and water, improved sanitation and food safety, safer environments and thus fewer injuries, and vaccines to […]
Under-the-radar Chinese biotech scores $47M upfront in secretive Merck deal around cancer drug
During his most recent investor call, Merck CEO Rob Davis promised to be “appropriately aggressive in pursuing compelling external innovation.” But as it turns out, that doesn’t necessarily mean they would be loud about it. China’s Kelun Pharmaceutical said the pharma giant has licensed a certain […]
PhRMA Report: More than 500 medicines in development to treat disorders of the blood | Nachricht
WASHINGTON, May 18, 2022 /PRNewswire/ -- Today, the Pharmaceutical Research and Manufacturers of America released a new report covering 549 medicines in development to potentially treat disorders of the blood, including blood cancers. These conditions pose a significant and ongoing unmet medical […]
GlobalData Plc: Big Data Crucial for Business Strategy Across the Pharma Value Chain
GlobalData Plc The global data and analytics market in the pharmaceutical sector was valued at $1.4 billion in 2020 LONDON, May 18, 2022 (GLOBE NEWSWIRE) -- The healthcare and pharmaceutical industry generates data in abundance in the form of physician notes, pathology reports, EHR, patient […]
Merck snaps up cancer drug from China’s Kelun in $1.4bn deal
Merck & Co has quietly added another drug to its immuno-oncology pipeline via an agreement with China’s Sichuan Kelun Pharmaceutical, and is keeping the details close to its chest. The US pharma group is paying $47 million in upfront payments to license rights to the undisclosed drug outside […]
Cerner Collaboration to Increase Access to Cancer Clinical Trials
The company's Learning Health Network t eams with Elligo Health Research and Freenome to Advance Early Cancer Detection KANSAS CITY, Mo. Cerner Corporation (NASDAQ: CERN ), Elligo Health Research ® and Freenome are collaborating to enable a clinical trial through the Learning Health Network to help […]
